|
MD and MPH, University of Kansas Medical School
Community and Family Medicine, Professor
Recent Scholarship:
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D,
Schuind A, Zahaf T, Innis B, Naud P, Carvalho N, Rotelli C, Teixeira J, Blatter
M, Korn A, Quint Wim, Dubin G for the GlaxoSmithKline HPV Vaccine Study
Group. "Efficacy of a bivalent L1 virus-like particle vaccine
in prevention of infection with human papillomavirus types 16 and 18 in young
women: a randomised controlled trial." Lancet 364:
1757-65, 2004.
Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM,
Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown
DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, HarperDM,
Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings
HL, Saah AJ, Barr E. "Prophylactic Quadrivalent human papillomavirus
(types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a
randomised double-blind placebo-controlled multicentre phase II efficacy
trial." Lancet Oncology. 6(5):271-8, 2005 May.
Wiley DJ, Harper DM, Elashoff D,
Silverberg MJ, Kaestle C, Cook RL, Heilemann M, Johnson L. "How condom
use, number of receptive anal intercourse partners and history of external
genital warts predict risk for external anal warts."
International Journal of STD & AIDS. 16(3):203-11,
2005.
Monsonego, J. [Harper DM]. EUROGIN. "HPV infections
and cervical cancer prevention. Priorities and new directions. Highlights of
EUROGIN 2004 International Expert Meeting, Nice, France, October 21-23,
2004." Gynecologic Oncology. 96(3):830-9, 2005.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. "Efficacy of a bivalent L1
virus-like particle vaccine in prevention of infection with human
papillomavirus types 16 and 18 in young women: A randomised controlled
trial" (vol 60, pg 171, 2005). Obstetrical
& Gynecological Survey 60(7):484-484, 2005.
Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski
B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G on behalf
of the HPV Vaccine Study Group. "Sustained Efficacy up to 4.5 years
of a bivalent L1 virus like particle vaccine against human papillomavirus types
16 and 18: follow-up from a randomised controlled trial."
Lancet 2006;367:1247-55.
Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR,
Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm
C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM,
Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen
KU, Sings HL, Tamms GM, Saah AJ, Barr E. "Immunologic responses
following administration of a vaccine targeting human papillomavirus Types 6,
11, 16, and 18." Vaccine. 2006 Jul 7;24(27-28):5571-83.
Epub 2006 May 15.
Interests:
Maintenance of women’s health
Recognition, prevention and treatment of disease
The impact of women’s health on men
Courses Taught:
Electives in women’s health research
|
